Objective:To measure prostaglandin E2 levels during labor induction with a sustained-release vaginal polymer insert (prostaglandin E2 insert) and to determine whether Bishop score change correlated with tachysystole.
Methods:Twelve primiparas and 12 multiparas were treated with a 0.3 mg per hour sustained-release polymer vaginal prostaglandin E2 insert for up to 24 hours. Bishop score was assessed at start and end of therapy, and serum samples were collected at 4-hour intervals. Prostaglandin E2 metabolite (PGEM) levels were measured by specific enzyme immunoassay.
Results:Exposure averaged 13.5 ± 7.2 hours. Four patients (16.7%, three nulliparas) had tachysystole. Mean PGEM levels increased from 187 ± 42 pg/mL at baseline to 548 ± 110 pg/mL at 12 hours (P < .05) and remained relatively stable thereafter. Nulliparas with Bishop score changes of four points or more had the highest increase, with average peak levels of 985 ± 109 pg/mL, compared with 452 ± 58 pg/mL for all others (P < .001). Patients with tachysystole had higher 4-hour (P < .01) and overall (P < .04) increases in PGEM level. Removal of the insert led to an average decrease of 335 pg/mL in PGEM levels (P < .01). The decrease correlated with the PGEM level measured before removal (r = .94, P < .0001) and the maximum PGEM increase from baseline (r = .94, P < .0001). The mean mixed venous cord PGEM level was 409 ± 375 pg/mL.
Conclusion:Administration of the prostaglandin E2 insert led to a sustained increase in circulating PGEM levels in women who had labor induction. Peak PGEM levels correlated with Bishop score improvement. Rapid increases in prostaglandin E2 levels might cause tachysystole.
1. Hennessey MH, Rayburn WF, Stewart JD, Liles EC. Preeclampsia and induction of labor: A randomized comparison of prostaglandin E2 as an intracervical gel, with oxytocin immediately, or as a sustained-release vaginal insert. Am J Obstet Gynecol1998;179:1204-1209.
2.
2. Stewart JD, Rayburn WF, Farmer KC, Liles EM, Schipul AH Jr, Stanley JR. Effectiveness of prostaglandin E2 intracervical gel (prepidil), with immediate oxytocin, versus vaginal insert (Cervidil) for induction of labor. Am J Obstet Gynecol1998;179:1175-1180.
3.
3. Turnquest MA, Lemke MD, Brown HL. Cervical ripening: Randomized comparison of intravaginal prostaglandin E2 gel with prostaglandin E2 gel plus laminaria tents. J Maternal Fetal Med1997;6:260-263.
4.
4. Hibbard JU, Shashoua A, Adamczyk C. Isamil M. Cervical ripening with prostaglandin gel and hygroscopic dialtors. Infect Dis Obstet Gynecol1998;6:18-24.
5.
5. Taylor AV, Boland J, Bernal AL, MacKenzie IZ. Prostaglandin metabolite levels during cervical ripening with a controlled-release hydrogen polymer prostaglandin E2 pessary. Prostaglandins1991;41:585-594.
6.
6. Denison FC, Calder AA, Kelley RW, The action of prostaglandin E2 on the human cervix: Stimulation of interleukin 8 and inhibition of secretary leukocyte protease inhibitor. Am J Obstet Gynecol1999;180:614-620.
7.
7. Chyu JK, Strassner HT. Prostaglandin E2 for cervical ripening: A randomized comparison of Cervidil versus Prepidil. Am J Obstet Gynecol1997;177:606-611.
8.
8. Ottinger WS, Menard MK, Brost BC. A randomized clinical trial of prostaglandin E2 intracervical gel and a slow release vaginal pessary for preinduction cervical ripening. Am J Obstet Gynecol1998;179:349-353.
9.
9. Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol1997;177:612-618.
10.
10. Bothwell W, Verburg M, Wynalda M, Daniels EG, Fitzpatrick FA. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetcs. J Pharmacol Exp Their1982;220:229-235.
11.
11. Demers LM, Brennecke SP, Mountford LA, Brunt JD, Turnbull AC. Development and validation of a radioimmunoassay for prostaglandin E2 metabolite levels in plasma. J Clin Endocrinol Metab1983;57:101-106.
12.
12. Amon E, Fossik K, Sibai B. Serial changes in the biophysical profile in patients undergoing cervical ripening with a controlled release PGE2 vaginal pessary. J Maternal Fetal Med1999;8:8-11.
13.
13. O'Brien WF, Knuppel RA, Cohen GR. Plasma prostaglandin metabolite levels after use of prostaglandin E2 gel for cervical ripening. Am J Obstet Gynecol1986;155:1037-1040.
14.
14. Greer IA, McLaren M, Calder AA. Vaginal administration of PGE2 for induction of labor stimulates endogenous PGE2 alpha production. Acta Obstet Gynecol Scand1999;69:621-625.
15.
15. Prasad RN, Roy AC, Kottegoda SR, Ratnam SS, Karim SM. Plasma levels of 13,14-dihydro-15-keto PGE2 after vaginal application of a new PGE2 film. Prostaglandins1985;29:269-272.
16.
16. MacKenzie IZ, Castle BM, Mountford L, Ferguson J, Brennecke S, Embrey MP. Prostaglandin release from preparations used vaginally for the induction of labour. Prostaglandins1987;34:939-946.
17.
17. MackEnzie IZ, Castle B, Bellinger J. Transfer of prostaglandins to the fetus after prostaglandin E2 vaginal pessary administration. Am J Obstet Gynecol1989; 161:920-923.
18.
18. McLaren M, Greer IA, Smith JR, Godfree V, Graham N, Calder AA. Maternal plasma bicycling PGE2 levels following vaginal administratiuon of prostaglandin E2 pessaries in full term pregnancies. Prog Clin Biol Res1987;242:199-203.
19.
19. Reichel R, Husslein P, GOschen K, Rasche M, Sinzinger H. Resorption of prostaglandin E2 following various methods of local administration for ripening of the cervix and end the induction of labor. Wien Klin Wochenschr1985;97:500-503.
20.
20. Voos DH, Cumminsky KC, Cook VD, Nethers MS, Spinnato JA, Gall SA. Effect of three concentrations of intracervical prostaglandin E2 gel for cervical ripening. J Maternal Fetal Med1996;5:186-193.
22. Glance DG, Elder MG, Myatt L Uptake, transfer and metabolism of prostaglandin E2 in the isolated perfursed human placental cotyledon. Prostaglandins Leukotriene Med1986;21:1-14.
23.
23. Johnston PC, Greer IA, Brooks NB. The transfer of prostaglandin E2 across ovine fetal membranes in vivo. J Soc Gynecol Invest1996;3:303-308.
